Skip to main content

Table 9 Safety profile

From: Xuan Bai Cheng Qi formula as an adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs: a multicenter, randomized, double-blind, placebo-controlled clinical trial

Variablesa XBCQb(n = 122) Controlb(n = 122) P- valuea
  Day 1 (Baseline) Day 10 (End) Day 1 (Baseline) Day 10 (End)  
WBC (109/L) 8.33 (3.49) 7.51 (2.81) 9.38 (7.95) 7.53 (3.11) .843
HB (g/L) 138.2 (24.0) 138.6 (31.0) 136.3 (28.1) 134.3 (28.1) .310
RBC (1012/L) 4.39 (0.65) 4.38 (0.64) 4.33 (0.61) 4.27 (0.57) .263
PLT (109/L) 198.4 (62.4) 210.4 (78.7) 209.4 (76.9) 207.5 (68.4) .178
NEUT (%) 69.6 (14.4) 64.7 (12.9) 68.9 (14.9) 62.1 (13.4) .111
ALT (U/L) 21.0 (11.1) 22.2 (12.1) 21.9 (16.3) 22.5 (14.1) .920
BUN (mmol/L) 5.6 (1.6) 5.7 (2.4) 6.1 (2.8) 5.8 (2.8) .511
CR ( μmmol/L) 75.4 (20.4) 74.0 (21.5) 85.2 (46.5) 80.3 (35.9) .863
BUN (n)c 27 (122) 32 (122) 15 (122) 7 (122) .116
ECG (n)c 56 (122) 45 (122) 57 (122) 47 (122) .895
  1. Abbreviations: ALT alanine aminotransferase, BUN blood urea nitrogen, Cr creatinine, ECG electrocardiogram, HB hemoglobin, NEUT neutrophilic granulocyte, PLT platelets, RBC red blood cell, WBC white blood cell.
  2. aCovariance analysis for between group after treatment. bData presented as mean (SD).
  3. cChi-square test for between group after treatment.